Mosunetuzumab, the First Bispecific Approved for Follicular Lymphoma

H&O What is mosunetuzumab (Lunsumio, Genentech) and how does it work? LEB Mosunetuzumab is a bispecific antibody-based T-cell engager with 2 binding sites. Unlike conventional monoclonal […]

Emerging Therapeutic Targets in Follicular Lymphoma

H&O What is the objective of the Wendel Laboratory? HGW We are interested in understanding the genetic and biologic mechanisms that lead to cancer in […]

RT @DrHKantarjian: The field of #BPDCN is rapidly evolving | Our new article by Dr. Pemmaraju @doctorpemm highlights the new era of ta… https://t.co/JSFnWqi49W

11 months ago
RT @ChelseaPinnix: Great summary of the important work that’s been done to improve outcomes in a rare disease. The future is bright.… https://t.co/PmNK5VOwvT

11 months ago
“Blastic Plasmacytoid Dendritic Cell Neoplasm: Emerging Developments and Special Considerations for 2023” by Naveen… https://t.co/EAEfwKrGjU

12 months ago
“Novel Approaches to the Treatment of Multiple Myeloma” by Kathryn T. Maples, PharmD, Sara A. Scott, PharmD, and Sa… https://t.co/9fIXqRSXxe

12 months ago